Damora Therapeutics, Inc. announced the voting results from its 2026 Annual Meeting of Stockholders held on June 17, 2026. Shareholders approved all proposals presented, including the election of two directors and the ratification of the company's independent auditor.
Key Details
- Director Election: Michael Landsittel and Cameron Turtle, D.Phil were elected as Class III members of the Board of Directors, each to serve until the 2029 Annual Meeting.
- Executive Compensation: Shareholders approved, on an advisory basis, the compensation of the company's named executive officers (Say-on-Pay proposal).
- Say-on-Pay Frequency: An annual frequency for future advisory votes on executive compensation was approved. The Board has adopted this annual frequency.
- Auditor Ratification: The selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.